Previous close | 0.1600 |
Open | 0.1600 |
Bid | 0.0300 |
Ask | 0.1700 |
Strike | 115.00 |
Expiry date | 2025-01-17 |
Day's range | 0.1600 - 0.1600 |
Contract range | N/A |
Volume | |
Open interest | 36 |
The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.